Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 9.3% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was down 9.3% during trading on Monday . The company traded as low as $0.25 and last traded at $0.25. Approximately 26,384,189 shares changed hands during trading, a decline of 60% from the average daily volume of 66,618,578 shares. The stock had previously closed at $0.28.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Thursday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 11.0 %

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a market cap of $46.37 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The firm’s 50-day simple moving average is $0.25 and its two-hundred day simple moving average is $0.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.